Product Program year 2025 Source: CMS Open Payments

Xgeva

Biological Oncology

NDC 55513-730-01

Open in the dashboard

General payments

$2,448,448

41,802 payments

Research payments

$16,217,907

425 payments

Through program year 2025, $2,448,448 in general payments and $16,217,907 in research payments were reported against Xgeva (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $5,714 249
2025 Research $215,539 17
2024 General $36,731 574
2024 Research $320,306 31
2023 General $105,726 4,618
2023 Research $2,291,830 39
2022 General $401,737 8,325
2022 Research $796,026 16
2021 General $455,441 7,572
2021 Research $1,673,228 45
2020 General $302,385 4,646
2020 Research $3,770,089 72
2019 General $1,140,713 15,818
2019 Research $7,150,889 205

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,448,448 41,802 payments
Top recipients General payments · program year 2025
  1. Jacob Moe Endocrinology, Diabetes & Metabolism · Farmington Hills, MI $142 2% · 1 payment
  2. Nira Madisi Endocrinology, Diabetes & Metabolism · Milford, DE $136 2% · 1 payment
  3. Sowmya Reddy Internal Medicine · Bronx, NY $136 2% · 1 payment
  4. Marie Guruli Internal Medicine · Hartford, CT $136 2% · 1 payment
  5. Onellis Stanford Nurse Practitioner, Family · Gulfport, MS $113 2% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $2,578 49% · 63 practitioners
  2. Internal Medicine $1,028 19% · 27 practitioners
  3. Endocrinology, Diabetes & Metabolism Internal Medicine $381 7% · 8 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $306 6% · 9 practitioners
  5. Physician Assistant $284 5% · 8 practitioners

The top 5 of 17 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Puerto Rico $3,070 54% · 77 recipients
  2. Michigan $796 14% · 13 recipients
  3. New York $332 6% · 6 recipients
  4. Georgia $164 3% · 7 recipients
  5. Texas $155 3% · 8 recipients

The top 5 of 28 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

14,372

Prescriptions dispensed, refills included

Drug cost

$45,204,571

Paid at the pharmacy, in all

Prescribers

451

With 11 or more claims of it

Medicare Part D drugs matched to XGEVA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Xgeva Denosumab Same name 451 14,372 $45,204,571

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Eugenio Galindo Hematology-Oncology TX 278 $848,943 None on record
Sanjaykumar Hapani Medical Oncology OK 246 $768,222 None on record
David Tamura Hematology-Oncology HI 181 $579,484 None on record
Michael Sherman Hematology-Oncology CA 179 $565,873 None on record
Ilmana Fulger Hematology-Oncology NY 162 $499,139 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to XGEVA
Billing code Providers Services Paid by Medicare
Injection, denosumab, 1 mg J0897 9,797 48,156,716 $978,864,125

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

41,802 general · 425 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record